98%
921
2 minutes
20
This column is the third in a 3-part series describing cases in which general medical knowledge, including psychiatric and clinical pharmacology, was instrumental in determining whether dereliction was the direct cause of damages in a malpractice suit. This case illustrates how not taking into account the following variables can result in a false-positive diagnosis of a lethal serotonin syndrome: (a) the time course of treatment, (b) the time course of symptoms, (c) the difference between antemortem plasma and postmortem whole-blood levels of highly protein bound and highly lipophilic drugs. The case also illustrates how taking those 3 variables into account led to the conclusion that there was no dereliction in the care of the patient that was the direct cause of his death, and hence, there was no medical malpractice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/PRA.0000000000000801 | DOI Listing |
Clin Gastroenterol Hepatol
September 2025
CIBERehd, Spain; SeLiver group, Instituto de Biomedicina de Sevilla; Hospital Universitario Virgen del Rocío; Universidad de Sevilla. Electronic address:
Background: &Aim:Resmetirom is the first FDA-approved drug for metabolic-associated liver disease(MASLD) in F2-F3 patients with steatohepatitis. Non-invasive criteria have been proposed for initiating treatment; however, these have not been validated in clinical practice. We validated the proposed criteria and established new guidelines for initiating resmetirom treatment in clinical practice.
View Article and Find Full Text PDFBehav Neurol
September 2025
Department of Electronics and Communication Engineering, Chettinad Academy of Research and Education, Manamai Campus, Chennai, Tamil Nadu, India.
Temporary disturbances in brain function are caused by epilepsy, a chronic disorder resulting from sudden abnormal firing of brain neurons. This research introduces an innovative real-time methodology representing detecting epileptic spasms from electroencephalogram (EEG) data. It employs a support vector machine (SVM) alongside embedded zero tree wavelet (EZW) transform.
View Article and Find Full Text PDFFront Oncol
August 2025
Department of Radiation Medicine, Oregon Health & Science University, Portland, OR, United States.
Purpose/objectives: Cancer screening continues to be a major challenge, with reliable tests only being available for very few cancers. Multi-cancer early detection (MCED) genomic tests are being developed that allow for blood-based screening of multiple cancers simultaneously. The PATHFINDER study was a multi-institution prospective cohort study in healthy participants over the age of 50 years (no cancer history, or history of treated cancer > 3 years prior), investigating the feasibility of the Galleri (GRAIL, LLC) cfDNA methylation MCED blood test.
View Article and Find Full Text PDFCancer Cytopathol
September 2025
Department of Pathology, University of Navarra Clinic, Navarra, Spain.
Lung cancer continues to be the leading cause of cancer-related mortality, with cytologic samples often serving as the primary diagnostic tool. However, differentiating between benign and malignant processes in lung cytology can be difficult because various non-neoplastic conditions closely resemble malignant lesions, which may lead to misdiagnosis. This review offers nine essential tips to help cytopathologists prevent false-positive diagnoses of malignancy in non-neoplastic processes.
View Article and Find Full Text PDFAJR Am J Roentgenol
September 2025
Department of Radiology, University of California, Los Angeles, 200 UCLA Medical Plaza, Los Angeles, CA, 90095.
By reliably classifying screening mammograms as negative, artificial intelligence (AI) could minimize radiologists' time spent reviewing high volumes of normal examinations and help prioritize examinations with high likelihood of malignancy. To compare performance of AI, classified as positive at different thresholds, with that of radiologists, focusing on NPV and recall rates, in large population-based digital mammography (DM) and digital breast tomosynthesis (DBT) screening cohorts. This retrospective single-institution study included women enrolled in the observational population-based Athena Breast Health Network.
View Article and Find Full Text PDF